Opioids are powerful painkillers and undoubtedly have a role to play in managing severe short-term and chronic pain, but it is their side effects which so often prove problematic. The sense of euphoria and wellbeing induced by opiates is recognized as highly addictive and naturally makes opiate-based drugs open to abuse.
Legitimate patients all too often resort to taking more than prescribed by their doctor or than is required to manage their pain, in order to chase the high, becoming physically and/or physiologically dependant in the process.
"In 2007, Purdue and three of its executives pleaded guilty in a federal court to charges of misleading regulators, doctors and patients over the risk of addiction and potential for abuse by misbranding OxyContin."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze